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Canadian Institutes of Health:
Research definition of palliative care:
Palliative care aims to improve the life of pa-
tients and families through the early identifi-
cation and impeccable management of
suffering associated with advanced illness and
emphasis on the positive aspects of life in-
clusive of physical, psychosocial and spiri-
tual sources. Palliative care is an exercise in
prevention—prevention of suffering through
prioritizing the diagnosis and skillful care of
sources of distress throughout the course of
illness and for the family into the bereave-
ment period. It is not simply an end of life
concept separate from other aspects of re-
search and control. Palliative care research
focuses on fundamental symptom mecha-
nisms as well as the experience of the patient
and the family.
—Adapted, with thanks, from the World
Health Organization
The preceding palliative care definition, endorsed by
the Canadian Institutes of Health Research (CIHR)
Institute of Cancer Research, emphasizes early iden-
tification of sources of suffering in cancer patients
and, by inference, the importance of clinical trials on
symptom-control therapies introduced early in a
patient’s course of illness. This noble objective is fully
in keeping with the reports of an influential panel
which recommends that patients and families have
access to the full range of care measures at disease
onset 1.
Today, few would disagree with the concept that
therapy for symptom and psychosocial problems
should be integrated with traditional measures of
curing or controlling cancer (surgery, radiotherapy,
chemotherapy). However, model programs blending
these elements of care from diagnosis are still not
common.
Cancer centres may be making progress in mov-
ing from rhetoric to reality, but slowly in the clinical
research sphere. For example, anorexia–cachexia is
often encountered early in the course of the illness,
but research on the problem is modest. In 2005, 15 of
4917 abstracts published by the American Society of
Clinical Oncology were concerned with cancer nu-
trition, including cancer cachexia. Only a few of these
were clinical trials, with small patient enrolment. No
progress was seen in 2006, with its 10 nutrition pre-
sentations. Research presentations on the problems
of chronic symptoms—aside from those on pain (a
dramatic, acute source of suffering demanding im-
mediate attention)—continue to lag.
Because of the common presence of cancer anor-
exia–cachexia as a source of patient–family distress,
and because of its devastating effects (loss of func-
tion, and consequent dependency and poorer progno-
sis), I will use that symptom as a theme to illustrate
problems in conducting clinical studies that need to
enlist patients early in the course of their illness.
DIFFICULTIES WITH TRIAL ENROLMENT AND
DROPOUT
I recently served as the Canadian Principal Investi-
gator (PI) for an international anorexia trial. Cana-
dian patients represented approximately 25% of the
patients enrolled in that study 2, but most came from
my home institution, one other academic centre, and
a community cancer centre; enrolment from our larg-
est cancer centres was poor. When the local investi-
gators were asked about their low enrolment, they
replied that they had had difficulty in keeping the
trial “front and centre” with their oncology colleagues.
Failure to recommend patients for the trial until
cachexia was far advanced was also a problem. An-
other major reason expressed for the delay in trial
consideration was competition with conventional
cancer chemoradiotherapy trials.
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Why “competition”?
Most clinical trials are sponsored by pharmaceu-
tical firms. For example, in 2005, our Institutional
Review Board at McGill University received 42 on-
cology studies, of which 30 were industry-sponsored
submissions. Sponsoring companies are usually in-
terested in conducting trials with narrow inclusion
criteria. These “fastidious” trials (defined as “using
homogeneous groups, reducing or eliminating ambi-
guity” 3) are designed to examine the use of a spe-
cific therapy in a carefully controlled environment,
leaving little doubt that any observed efficacy directly
relates to the tested product. This aim is sensible, and
expected by regulatory authorities, but it leads to a
trial milieu that may not reflect the general practice
of oncology. “Pragmatic” trials—defined as those that
“would incorporate heterogeneity, occasional or fre-
quent ambiguity, and other ‘messy’ aspects of clini-
cal practice” 3 are more relevant to actual oncology
practice, but are less commonly conducted. The pro-
tocols for fastidious trials usually contain an exclu-
sion clause with wording along the following lines:
“Concomitant employment of other experimental
therapies during the course of the clinical trial is
prohibited” 3.
Inherently, a paradox is evident. The cancer com-
munity believes that research into palliation and
symptom control deserves a high priority 4 and that
that research should commence with the onset of a
symptom (for example, as soon as a weight-losing
patient with lung cancer presents with disease). How-
ever, the same patient cannot go on a symptom con-
trol trial if enrolled in a chemotherapy study, because
participation in another clinical trial is proscribed.
Consequently, late in the course of illness, a small
coterie of exhausted patients with profound weight
loss may now be asked if they wish to consider en-
listing in a cachexia trial. But is this trial hierarchy
logical?
Exclusion of patients from participation in two
simultaneous trials is usually justified for these
reasons:
• Regulatory authorities will not permit simulta-
neous trials.
• Participation in two trials will present confound-
ing information that will make it impossible for
the pharmaceutical firm to properly study the ef-
ficacy of the drug or drug and radiotherapy com-
bination of interest and to accurately assign
adverse reactions.
These excellent reasons fail to take note of cer-
tain confounding facts. Many patients with advanced
cancer are using a variety of untested combinations
of diet, supplements, vitamins, herbs, naturopathic
products, yoga, and so on 5. Pharmaceutical trials have
not usually controlled for these widespread potential
confounders. Moreover, the populations at risk for
cancer tend to be older, and they often have comor-
bid conditions—notably diabetes, hypertension, car-
diovascular disease, and chronic obstructive
pulmonary disease. Patients with these disorders are
thus receiving a wide variety of drugs that could af-
fect disease activity 6–8 and certainly may interfere
with drug metabolism. Information on these agents
and their relevance usually does not appear in study
reports.
Excluding careful clinical research observations
on agents aimed at helping control symptoms, while
ignoring the chaotic, uncontrolled potential effects
of alternative and non-cancer-related therapies on
drug and radiotherapy response is therefore illogi-
cal. From a statistical point of view, patients who
are also engaged in a symptom control trial can be
readily stratified, although trials may then need to
be larger.
We worship at the “evidence based” altar. Many
of our symptom control trials are lightly regarded
because of small patient enrolment and high dropout
rates from death and increasing frailty. Here are some
examples from two recent studies published by lead-
ers in the anorexia–cachexia field:
• Fearon and colleagues 9 recently reported on the
efficacy of two doses of an omega-3 fatty acid
on pancreatic cancer–induced cachexia. A robust
effect was not found, only a favourable trend at
the level of a 2-g dose of eicosapentaenoic acid.
The mean weight loss on trial entrance was 18%,
and the dropout rate among these profoundly ill
patients was approximately 50% over 8 weeks.
• The recent article by Strasser et al. 10 on cannab-
inoid use in combating anorexia had a 32% drop-
out rate in 8 weeks; the study population had a
mean weight loss of 11.9% upon enrolment.
We will not advance cachexia research until we
can invite people with early weight loss to consider
trial participation.
OBLIGATION TO DEVELOPING COUNTRIES
Recent advances have come at a cost—a cost passed
on to the health system, or now, frequently, to the
patient as governments lag in picking up the tab for
non-curative, extraordinarily expensive therapies that
may modestly prolong survival for a select group of
patients. To paraphrase the Etruscan general Pyrrhus’
comment on winning a battle with the Romans at great
cost to his army, “A few more pharmaceutical ad-
vances like cetuximab and our cancer care system is
bankrupt.”
The costs of new anticancer agents create major
dilemmas in Canada. What about resource-poor coun-
tries such as those of the African continent? Those
countries will never be able to pay for drugs like
bevacizumab or cetuximab. Do we have an ethicalADVANCING CANCER SYMPTOM CONTROL TRIALS
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obligation to carry out clinical trials using inexpen-
sive agents which, while not commercially profitable,
may be more available to poor countries?
Recent ideas for cachexia trials include, among
others, combinations of inexpensive anti-inflamma-
tory agents with stimulants of muscle synthesis. If
this research is successful, the fruits could be widely
used. Moreover, the outcomes of these “pragmatic
trials” may more readily predict response in a gen-
eral cancer population. Our research sponsors, includ-
ing the pharmaceutical industry, must consider the
plight of cancer patients in poor lands and direct some
research support into studies on agents that can be
more readily accessed.
CONCLUSION
On ethical and scientific grounds alike, exclusion of
options for participation in symptom control trials
by newly diagnosed patients does not stand up to
scrutiny. I suggest that the following clinical trial
policies are worthy of consideration:
• In the absence of clear ethical or scientific rea-
soning, patients enrolled in chemotherapy and
radiotherapy trials should be able, at the same
time, to participate in symptom control trials. If
the sponsoring company or PI demands that the
exclusion clause barring patients from symptom
control studies must stand, the onus should be
on the company or the PI to provide evidence
that this demand is ethically and scientifically
justified.
• If symptom control studies are available to pa-
tients presenting at any stage of their disease, it
is imperative that an investigator fully inform the
patients of the opportunity for participation in
symptom control trials in addition to other trials
under discussion.
• A new trial hierarchy should be established
wherein trials with probable major impact on tu-
mour response rank at the top (as they now do).
• The second rank should include pragmatic tri-
als in which patients may receive chemoradio-
therapeutic study agents and still enrol in
symptom studies—that is, pragmatic trials
should receive a higher ranking than they do
at present.
• The third rank could include fastidious trials.
• In the fourth rank are the “me too” trials—the
ones that are often lucrative, but that are not
providing much in the way of new knowledge.
A variant of an existing agent usually has simi-
lar properties and probable modest efficacy and
safety distinctions. These trials should not,
however, congest the clinical trials structure.
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